{"id":"W2220367249","doi":"10.1200/jco.2007.25.18_suppl.4030","title":"XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Capecitabine; Oxaliplatin; Medicine; Irinotecan; Bevacizumab; Internal medicine; Colorectal cancer; Population; Oncology; Fluorouracil; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003090832,0.002248457,0.002540428,0.0004375302,0.0004128032,0.0008614303,0.0009175464,0.00192878,0.00689552],"category_scores_gemma":[0.00165515,0.0005796775,0.00173339,0.0003198677,0.00115912,0.0009991907,0.0004939827,0.004086631,0.0008938122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006741035,"about_ca_system_score_gemma":0.0009981965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005102078,"about_ca_topic_score_gemma":0.001428501,"domain_scores_codex":[0.9990652,0.0006156173,0.00003783881,0.0001065685,0.00006943233,0.0001052658],"domain_scores_gemma":[0.9990771,0.0002538045,0.0002053708,0.00006074219,0.00003541746,0.0003677103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.965198,0.01154664,0.0005138676,0.0004586034,0.0004907406,0.0000443565,0.00005274708,0.0003772415,0.003286337,0.0000880361,0.001260214,0.01668318],"study_design_scores_gemma":[0.8656579,0.1310739,0.001418946,0.00001916894,0.0002820223,0.00003910497,0.00001240944,0.0002821437,0.000467407,0.00009743057,0.000635079,0.00001453692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865406,0.00440266,0.0005940917,0.001047271,0.0005053937,0.003297876,0.001441348,0.0001131774,0.002057699],"genre_scores_gemma":[0.9798141,0.003229362,0.001562386,0.002000511,0.0007994427,0.003504097,0.002723532,0.00004658594,0.006320019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00689552,"threshold_uncertainty_score":0.02306777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1377486985361567,"score_gpt":0.4849429064891192,"score_spread":0.3471942079529625,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}